[IntegReview IRB - IAA] A Phase 1 Open-label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and Pharmacokinetics of HPN424 in Patients with Advanced Prostate Cancer Refractory to Androgen Therapy
The purpose of this study is to test the good and/or bad effects, mechanism of action, and efficacy of an experimental drug called HPN424 in participants with advanced prostate cancer. Additionally, the study will analyze how the body metabolizes the study drug over time.
Metastatic castration resistant prostate cancer(mCRPC)
-Subjects should have metastatic castration-resistant prostate cancer.
-Subjects should have at least two prior systemic treatment approved for the castration-resistant setting
-Subjects may previously be treated with a second-generation hormone therapy (eg, enzalutamide or equivalent or with abiraterone acetate).
-Subjects should not have concurrent or recent treatment with drugs that help stop inflammation, systemic steroids, or other immune suppressive drugs.
-Subjects should not have any history of or current brain metastases.
18 - NA
Healthy Volunteers Needed
Duration of Participation
Participants will receive the investigational drug for up to 3 years. There will be one follow up visit 28 days after the last dose of the study drug. After discontinuation of the study drug, participants will be contacted by phone monthly for 6 months and every 3 months thereafter.
Clinical Trials Information Line: Phone 503-494-1080 or firstname.lastname@example.org
Harpoon Therapeutics, Inc.